Osteochondroma after total body irradiation in bone marrow transplant recipients: report of two cases

Japanese Journal of Clinical Oncology
G MaedaM Ohira

Abstract

We present two cases of osteochondroma after total body irradiation in bone marrow recipients, the first in a 6-year-old boy with juvenile chronic myelogenous leukemia and the second in a 13-year-old boy with acute myelogenous leukemia. The patients developed multiple osteochondromas three years and seven years, respectively, after 12 Gy of total body irradiation. Neither had a family history of hereditary multiple osteochondromatosis. A review of the English literature revealed only one report describing five cases of osteochondroma after 12 Gy of total body irradiation in bone marrow transplant recipients. Osteochondroma should be considered as an additional adverse effect of total body irradiation.

Citations

Aug 17, 1973·Clinica Chimica Acta; International Journal of Clinical Chemistry·Z TamuraJ Kusaka
Jul 9, 2002·British Journal of Haematology·Alison D Leiper
Mar 30, 2010·Malawi Medical Journal : the Journal of Medical Association of Malawi·Biruk L WamishoMihiret W Tinsay
Mar 3, 2015·Cancer·Brian H KushnerNai-Kong V Cheung
Sep 15, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Maura FaraciUNKNOWN AIEOP-HSCT Group
Mar 17, 2015·The Orthopedic Clinics of North America·Felasfa M Wodajo
Apr 30, 2002·Bone Marrow Transplantation·P BordigoniF Plenat
Apr 20, 2007·Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging·Sasa Zivković
Jan 17, 2012·Journal of Pediatric Hematology/oncology·Yoji ShidoYoshihiro Nishida
Dec 30, 2017·Pediatric Blood & Cancer·Taylor J JacksonAlexandre Arkader
Nov 28, 2018·Hormone Research in Pædiatrics·Sogol Mostoufi-Moab, Leanne M Ward

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.